Roche makes four pipeline changes on back of tri­al fail­ures, but sees path ahead for three ther­a­pies

Roche is re­work­ing its plans for a quar­tet of clin­i­cal pro­grams span­ning dif­fer­ent ther­a­peu­tic ar­eas and stages of de­vel­op­ment, but it may not be the end of the road for most of the drugs af­fect­ed.

The Swiss drug­mak­er re­vealed it was drop­ping its Phase I sol­id tu­mor tri­al for cibisa­tam­ab, as well as Phase II pro­grams for ralmi­taront in schiz­o­phre­nia and vi­cas­in­abin in di­a­bet­ic retinopa­thy, ac­cord­ing to a pipeline doc­u­ment re­leased as part of Thurs­day’s third-quar­ter earn­ings up­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER